Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025

Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025

 
 
  • Four expert-led educational events with Allergan Medical Institute (AMI), Science of Aging TM and Allergan Aesthetics (AA) Global Medical Affairs
  •  
  • AMI symposia will focus on a new Allergan Aesthetics (AA) Signature Program and celebrate 10 years of MD Codes™, with live injection sessions and fireside chat with world-renowned plastic surgeon Dr. Maurício de Maio
  •  
  • Eleven E-Poster data presentations and Meet the Expert sessions with Global experts live from the Allergan Aesthetics booth
  •  

Allergan Aesthetics, an AbbVie company, the industry leader in aesthetics globally, demonstrates how to elevate the patient experience and achieve optimal treatment outcomes with new AA Signature program at the Anti-Aging and Aesthetics Medicine World Congress (AMWC) in Monaco from Thursday, March 27Saturday, March 29, 2025 .

 

Activities will center around the new AA Signature program - an innovative approach to treatment planning harnessing the power of Allergan Aesthetics advanced portfolio to address different patient needs, including Lift, Definition and Skin Quality , and a celebration of 10 years of MD Codes™, which has revolutionized aesthetic medicine with innovative methodology to guide injectors' technique and elevate patient outcomes.

 

  AMI Symposia
Meetings will take place as follows:

 
  •    Design your patients' look with the NEW Signature approach by Allergan Aesthetics.   11.15 AM – 1:15 PM on Thursday, March 27 in the Salle des Princes, Grimaldi Forum.
  •  
  •    MD Codes™ and Allergan Aesthetics: a decade of excellence and a signature of success for the future.   9:45 AM– 12:45 PM on Friday, March 28 in the Salle des Princes, Grimaldi Forum.
  •  

The first AMI symposium, ' Design your patients' look with the NEW Signature approach by Allergan Aesthetics ' , will include:

 
  • Two key signature looks from the AA Signature program - 'Lif   t Up' and 'Distinct Definition' .
  •  
  • The meeting will be co-chaired by leading experts Dr. Stefania Roberts (ANZ) and Dr. Andre Braz (Brazil), who'll facilitate discussions and live injections sessions with Dr. Sylwia Lipko-Godlewska ( Poland ), Dr. Marcel Vinicius (Brazil) and Dr. Lu Wang ( China ).
  •  

Day two will open with '    MD Codes™ and Allergan Aesthetics: a decade of excellence and a signature of success for the future'    . Highlights will include:

 
  • A deep dive into MD Codes™, its global presence and impact led by Dr. Maurício de Maio (Brazil) , Dr. Nelson Chang ( China ), Dr. Iman Nurlin ( Sweden ), Dr. Sylwia Lipko-Godlewska ( Poland ) and Dr. Marcel Vinicius (Brazil).
  •  
  • Expert speakers, live injection sessions and a fireside chat with Dr. Maurício de Maio who will explore the ongoing significance of hyaluronic acid as a key component in the modern multimodal treatment approach.
  •  

  Beyond the AMI Symposia
Events will take place as follows:

 
  •   Science of Aging    TM   Symposium . 4:30 PM – 6:30 PM on Thursday, March 27 in the Auric Room, Grimaldi Forum.
  •  
  •   Global Aesthetics Medical Affairs Symposium . 2:00 PM – 4:00 PM on Friday, March 28 in the Pinède1 room, Diaghilev level, Grimaldi Forum.
  •  

  Exclusive   Science of Aging    TM   Symposium: 'Bold scientific advances for a new age'   brings together world-class experts to present the bold scientific advances within the field of aging. Dr. Stephanie Manson Brown, Vice President of R&D, Head of Clinical Development at Allergan Aesthetics, and Dr. Patricia Ogilvie ( Germany ) will open the event, followed by the discussion of key topics including skin longevity, genomics of aging, epigenetics of skin and mitraclock with Dr. Anne Chang from Stanford University (US), Dr. Howard Jacob from AbbVie (US) and Dr. Cristiana Banila of Mitra Bio (UK). The event will conclude with an engaging Q&A led by event chair Dr. Patricia Ogilvie.

 

  Global Aesthetics Medical Affairs Symposium : '   Socially Transformative Aesthetic Medicine Impacting Emotion and Social Perception    ' will explore the multidimensional aspects of aesthetic medicine, and how aesthetic treatments not only enhance physical appearance but can also significantly impact emotional well-being and social perception. Chaired by Dr. Steven Dayan (US) alongside Dr. Sarah Boxley ( Australia ), Dr. Mitchell Brin (US), Prof. Dr. Dario Bertossi ( Italy ), and Dr. Ligia Colucci (Brazil), the expert panel will discuss the scientific data and provide clinical insights with transformative patient stories.

 

  Meet the Experts  
Meet the Experts sessions will be live from the Allergan Aesthetics booth, showcasing:

 
  •    AA Signature – Delivering a 360 approach to skin quality   with Dr. Marion Runnebaum , Germany .
  •  
  •    Defining the lower face: The AA Signature Distinct Definition approach   with Dr. Wenjin Wang , China .
  •  
  •    Celebrating 10 years of the MD Codes: Shaping your practice and treatment approach   with Dr. Raafat Lakis ,   Dubai   and Dr. Sheila Mulatti, Brazil.
  •  
  •    Optimising periorbital treatment to target aging effects: The Eye IMPACT study   with Dr. Sarah Boxley, Australia .
  •  

Across three days, the Allergan Aesthetics immersive booth (P3) will be a discovery hub for exploring the new AA Signature Program, where visitors can get hands-on with the portfolio, meet industry experts, experience the latest innovation in AA digital applications, and sign up to AMI Digital World.

 

  E-Poster Sessions
Allergan Aesthetics' commitment to driving industry with advancing science and clinical data is demonstrated with the acceptance of 11 E-posters. The E-Posters will showcase the latest data and science supporting Allergan Aesthetics brand portfolio, looking specifically at the Skin Quality Lexicon and the multimodal approach of the Eye Impact Study.

 

  Titles and named authors for the 11 posters to be showcased at AMWC:  

 
 
                                    
 

   Presentation Topic   

 
 

   Poster Title   

 
 

   Authors   

 
 

  HArmonyca Int'l Study - Interim ABS  

 

 

 
 

  An International, Multicenter, Evaluator-blinded, Randomized, Parallel-Group, Controlled Study of the Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation  

 
 

  Andreas Nikolis, Nestor Demosthenous, Shannon Humphrey, Fernando Urdiales, Malka Salomon, Andrew Schumacher  

 
 

  HArmonyca MDR Final ABS AMWC Monaco  

 

 

 
 

  Prospective, Open-label, Post Marketing Study of the Safety and Effectiveness of HArmonyCa Injectable Gel for Mid Face Soft Tissue Augmentation  

 

 

 
 

  Alessandro Gritti, Andrew Schumacher, Malka Salomon, Graeme Kerson  

 
 

  SQ Attribute Definitions Part 2 ABS  

 
 

  Establishing a Vocabulary for Skin Quality: Working Toward Consensus Skin Attribute Definitions From the Patient and Physician Perspective  

 
 

  Shannon Humphrey, Derek Jones, Heather Woolery-Lloyd, Angeline Yong, Stephanie Manson Brown, Heather Lampel, Julie Garcia, Sherket Peterson  

 
 

  MMP Psychosocial Impact HEOR - AMWC Monaco 2025 ABS  

 
 

  Psychosocial Impact of Masseter Muscle Prominence: Patient Perspectives Across Multiple Regions  

 

 

 
 

  Catherine Foley, Julia Garcia, Martha Gauthier, Greg J Goodman, Shannon Humphrey, Taro Kono, Elisabeth Lee, Grace Pan, Yan Wu  

 
 

  Platysma Integrated Ph3 PRO 309/310 AMWC Monaco 2025 ABS  

 
 

  OnabotulinumtoxinA for the Treatment of Platysma Prominence: Patient-Reported Outcomes From 2 Phase 3 Multicenter, Randomized, Double-blind, Placebo-Controlled Studies  

 

 

 
 

  Joely Kaufman, William P. Coleman, Amir Moradi, Steven Dayan, Patricia Ogilvie, Ava Shamban, Steve Yoelin, Warren Tong, Sandhya Shimoga  

 
 

  Platysma Ph3 323 OL Extension AMWC Monaco 2025 ABS  

 
 

  Repeat Treatments of Moderate to Severe Platysma Prominence With OnabotulinumtoxinA Has a Favorable Safety Profile in a Long-term, Phase 3, Open-label Extension Study  

 
 

  Terrence Keaney, Kenneth Beer, William Hanke, Ira Papel, Deanne Mraz, Rodney Rohrich, Susan Weinkle, Steven Yoelin, Warren Tong, Rene Hopfinger  

 
 

  Platysma Ph3 323 OL PRO AMWC Monaco 2025 ABS  

 
 

  Patient-Reported Outcomes Across Repeat Treatments for Moderate to Severe Platysma Prominence in a Long-term, Phase 3, Open-label Extension Study  

 
 

  Shannon Humphrey, Sue Ellen Cox, Roy Geronemus, Terrence Keaney, Deanne Mraz, Jennifer Nash, James Pehoushek, Rodney Rohrich, Rene Hopfinger, Sandhya Shimoga  

 
 

  Natural Look Satisfaction Scale Botox AWMC Monaco 2025 ABS  

 
 

  Development of the Natural Look Satisfaction Scale for the Treatment of Upper Facial Lines With Neurotoxin  

 
 

  Tanya Brandstetter, Annaliza Dominguez, Julia Garcia, Julie Whyte, Martha Gauthier, Kian Karimi, Steve Yoelin, Carmen Kavali  

 
 

  Vycross Botox Eye Impact - Upper / Midface Tx ABS  

 
 

  Improving Infraorbital Hollow Severity and Volume Through Mid- and Upper-Face Treatment With Hyaluronic Acid (HA)-Fillers and OnabotulinumtoxinA  

 
 

  Gregory J Goodman, Samira Baharlou, Sarah Boxley, Pierre Cuvelier, Cara McDonald, Joan Vandeputte, Ivar Van Heijningen, Julia Garcia, Traci Baker, Smita Chawla, Carola de la Guardia, Frank Lin  

 
 

  Vycross Botox Eye Impact PRO ABS  

 
 

  Improvements in Age Perception and Psychological Well-Being After Rejuvenation of the Eye Area Using Hyaluronic Acid-Based Fillers and OnabotulinumtoxinA in the Mid- and Upper-Face  

 
 

  Gregory J Goodman, Samira Baharlou, Sarah Boxley, Pierre Cuvelier, Cara McDonald, Joan Vandeputte, Ivar Van Heijningen, Julia Garcia, Traci Baker, Smita Chawla, Carola de la Guardia, Frank Lin  

 
 

  Vit C&E after Picosecond Laser Treatment  

 

 

 
 

  Improvement in Skin Quality Using Vitamin C+E Complex Antioxidant Serum After Picosecond Laser Treatment  

 

 

 
 

  Yang Qui, Caroline Aguilar, Johnny Chen, Kate Huang, Elizabeth T. Makino, Monica Zhu, Huangde Li  

 
 
 

  Notes to Editors  

 

  About AbbVie  

 

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at   www.abbvie.com   . Follow @abbvie on   LinkedIn,     Facebook   ,   Instagram   ,   X (formerly Twitter)   , and   YouTube   

 

  About Allergan Aesthetics  

 

At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com  

 

  Forward-Looking Statements  

 

  Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.  

 
 
  
 

    Global Media:    

 

  Michael Salzillo  

 

  michael.salzillo1@allergan.com  

 

 

 

   U.S. Media:   

 

  Adelle Infante  

 

  Adelle.infante@allergan.com  

 
 

    Investors:    

 

  Liz Shea  

 

  liz.shea@abbvie.com  

 
 
 

*AA Signature, by Allergan Aesthetics, is a new program that Internationally in February 2025 and will be considered for roll out across International markets, as appropriate, over the next year.

 
 

  Allergan Aesthetics (PRNewsfoto/AbbVie) 

 
 
 
 

 Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/allergan-aesthetics-emphasizes-commitment-to-innovation-science-and-a-patient-centric-approach-at-amwc-2025-302409039.html  

 

SOURCE AbbVie

 
 

 

News Provided by PR Newswire via QuoteMedia

ABBV:US
The Conversation (0)
AbbVie Inc.

AbbVie Inc.

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This establishes the timeline for the planned safety and efficacy futility interim analysis by an independent Data Monitoring Committee (DMC).

Keep reading...Show less
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less
Zoono Group

Exclusive UK Packaging Agreement signed between Sharpak Aylesham Limited, Zoono, and OSY

Zoono Group Limited (Company) (ASX: ZNO) is pleased to update the market on an exclusive contract signed with Sharpak Aylesham Limited (Sharpak) and the Company’s partner in the food supply chain sector, OSY Group Limited (OSY).

Keep reading...Show less
Amplia Therapeutics

Accent Trial Data Demonstrates that Narmafotinib + Chemotherapy Combination Superior to Chemotherapy Alone

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce important new data from our ongoing ACCENT clinical trial in pancreatic cancer. The trial is investigating the Company’s best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane. Fifteen (15) confirmed partial responses (PRs) have now been recorded in the trial, a level of response sufficient to demonstrate that the combination of narmafotinib and chemotherapy is superior to chemotherapy alone.
Keep reading...Show less

Latest Press Releases

Related News

×